ReGen Biologics Inc. (RGBOQ) Research

ReGen Biologics Inc., established in 1987 and headquartered in Hackensack, New Jersey, specialized in the development, manufacturing, and commercialization of medical devices. These devices were engineered for the restoration and growth of soft human tissues, particularly within orthopedic fields. The company's core asset was its unique collagen matrix technology, which found broader utility across various medical disciplines including general surgery, spinal care, cardiovascular applications, and drug delivery. Key product offerings included the Menaflex collagen meniscus implant, designed for reinforcing and repairing soft tissue damage to the medial meniscus during surgery, and the SharpShooter Tissue Repair System, an instrument that assisted surgeons in accurately placing needles in difficult-to-access meniscus regions. ReGen Biologics distributed its products internationally to countries such as the United States, the European Union, South Africa, Canada, Australia, Chile, and Japan. Originally named Aros Corp, the company adopted the ReGen Biologics Inc. moniker in November 2002. Facing financial challenges, ReGen Biologics Inc. filed for Chapter 11 bankruptcy on April 8, 2011, in the U.S. Bankruptcy Court for the District of Delaware, ultimately leading to a Chapter 11 liquidation approved on October 14, 2011.

Open ReGen Biologics Inc. (RGBOQ) in Thesis for live fundamentals, charts, options context, and portfolio-aware Copilot follow-ups.